ARVN · Healthcare · $499M
$7.74+3.13%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
3/'26
12/'25 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“아르비나스는 세계 최초로 'PROTAC 분해제'라는 새로운 방식의 신약(VEPPANU)을 FDA 승인까지 이끈 회사예요.”
In the company's words · 2026 1분기 earnings call